Literature DB >> 26907667

The diagnosis, prognosis, and therapeutic application of MicroRNAs in haematological malignancies.

Xin Li1, Hua Zhong1.   

Abstract

OBJECTIVE: MicroRNAs (miRNAs) are small noncoding RNA molecules that participate in vital cell processes such as proliferation, apoptosis, and differentiation. In recent years, they have been proven to play vital roles in haematological malignancies. In this review we briefly introduce some basic knowledge of microRNAs and summarize their ectopic expression in haematological malignancies, especially in leukaemia. We will also discuss the potential of microRNAs in the diagnosis of leukaemia, in the determination of the clinical prognosis of diverse subtypes, and in targeted therapy. DISCUSSION: Despite current adoption of novel biological agents combining traditional chemotherapy regimens, leukaemia remains to have undesirable clinical outcomes due to inaccurate diagnosis, invasiveness of the disease, and patients' intolerance to chemotherapy, thus brand new therapeutic directions are urgently needed. MiRNAs regulate gene expression by means of binding to the 3'-untranslated regions of corresponding mRNAs, leading to the degradation of targeted mRNA or the inhibition of translation. It has been confirmed that they can either function as tumour inhibitors, or may trigger tumourigenesis in certain situations, this specific dual characteristic undoubtedly attract scientists to explore their roles in haematological malignancies. It is of great necessity to summarize the roles of miRNAs in haematological malignancies diagnosis, prognosis evaluation, and clinical treatment.
CONCLUSIONS: Future studies may take full advantage of miRNAs detection in diagnosing, in choosing targeted biological therapy, and in avoiding predictable side effect, thus the overall survival rate and cure efficiency of leukaemia should improve.

Entities:  

Keywords:  Biomarkers; Clinical prognosis; Ectopic expression; Haematological malignancies; MicroRNAs; Targeted therapy

Mesh:

Substances:

Year:  2016        PMID: 26907667     DOI: 10.1080/10245332.2015.1114766

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  4 in total

1.  miR-223 decreases cell proliferation and enhances cell apoptosis in acute myeloid leukemia via targeting FBXW7.

Authors:  Yi Xiao; Changliang Su; Taoran Deng
Journal:  Oncol Lett       Date:  2016-09-09       Impact factor: 2.967

Review 2.  Targeting microRNA in hematologic malignancies.

Authors:  Zhen Han; Steven T Rosen; Christiane Querfeld
Journal:  Curr Opin Oncol       Date:  2020-09       Impact factor: 3.915

Review 3.  Abnormal microRNA expression in the course of hematological malignancies.

Authors:  Agnieszka Szymczyk; Arkadiusz Macheta; Monika Podhorecka
Journal:  Cancer Manag Res       Date:  2018-10-08       Impact factor: 3.989

4.  Diagnostic and prognostic significance of aberrant miR-652-3p levels in patients with acute decompensated heart failure and acute kidney injury.

Authors:  Jiaolei Liu; Hongmei Zhang; Xin Li; Lin Wang; Huining Yu; Jiaohong Huang; Qingjun Liu; Chao Wang; Aili Jiang
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.